With Stock Rising, Anthera Prices $50M Offering for Lupus Program
By Trista Morrison
Monday, June 6, 2011
Although Anthera Pharmaceuticals Inc. already had sufficient funding to complete its ongoing Phase III trial with varespladib for acute coronary syndrome and its ongoing Phase II trial with blisibimod for lupus, the biotech raised $50 million in a public stock offering.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.